NDLI: The cellular level of histone H3 lysine 4 dimethylation correlates with response to adjuvant gemcitabine in Japanese pancreatic cancer patients treated with surgery.

Please wait, while we are loading the content...

Minimum incision endoscopic radical cystectomy in patients with malignant tumors of the urinary bladder: clinical and oncological outcomes at a single institution.

Outcome reporting for reconstructive breast surgery: the need for consensus, consistency and core outcome sets.

Reclassification of tumour origin in resected periampullary adenocarcinomas reveals underestimation of distal bile duct cancer.

RUNX3 methylation in normal surrounding urothelium of patients with non-muscle-invasive bladder cancer: potential role in the prediction of tumor progression.

Influence of low-molecular-weight heparin dosage on red blood cell transfusion, lymphocele rate and drainage duration after open radical prostatectomy.

Long-term outcome of breast cancer patients treated with radiofrequency ablation.

Temporary percutaneous ileostomy versus conventional loop ileostomy in mechanical extraperitoneal colorectal anastomosis: a retrospective study.

Meta-analysis of the risk for anastomotic leakage, the postoperative mortality caused by leakage in relation to the overall postoperative mortality.

Papillary breast lesions diagnosed by core biopsy require complete excision.

Treatment outcomes and unfavorable prognostic factors in patients with occult breast cancer.

The cellular level of histone H3 lysine 4 dimethylation correlates with response to adjuvant gemcitabine in Japanese pancreatic cancer patients treated with surgery.

Year: 2012 Volume: 38 Issue: 10

Year: 2012 Volume: 38 Issue: 8

Year: 2012 Volume: 38 Issue: 7

Year: 2012 Volume: 38 Issue: 6

Year: 2012 Volume: 38 Issue: 5

Year: 2012 Volume: 38 Issue: 4

Year: 2012 Volume: 38 Issue: 3

Year: 2012 Volume: 38 Issue: 2

Year: 2012 Volume: 38 Issue: 1

Year: 2011 Volume: 37

Year: 2010 Volume: 36

Year: 2009 Volume: 35

Year: 2008 Volume: 34

The cellular level of histone H3 lysine 4 dimethylation correlates with response to adjuvant gemcitabine in Japanese pancreatic cancer patients treated with surgery.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Watanabe, T. Morinaga, S. Akaike, M. Numata, M. Tamagawa, H. Yamamoto, N. Shiozawa, M. Ohkawa, S. Kameda, Y. Nakamura, Y. Miyagi, Y.
Description	Country affiliation: Japan Author Affiliation: Watanabe T ( Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 1-1-2 Nakao, Asahi-ku, Yokohama, Kanagawa-ken 241-0815, Japan. twgiraud@gmail.com)
Abstract	BACKGROUND: To search for biomarkers identifying pancreatic cancer patients likely to benefit from adjuvant gemcitabine chemotherapy, we investigated the status of several histone modifications in pancreatic tumors and their relationship to clinicopathological features and outcomes. METHODS: Sixty one pancreatic cancer patients, primarily treated by surgical removal of tumors, were involved in the study. Thirty patients completed postoperative adjuvant gemcitabine, and in 31 it was discontinued. Tumor specimens were examined using immunohistochemistry for di- and tri-methylation of histone H3 lysine 4 (H3K4me2 and H3K4me3), dimethylation and acetylation of histone H3 lysine 9 (H3K9me2 and H3K9ac), and acetylation of histone H3 lysine 18 (H3K18ac). Positive tumor staining for each histone modification was used to classify patients into low- and high-staining groups, which were examined for relationships to clinicopathological features and clinical outcomes. RESULTS: High expression of H3K4me3 was related to the well and moderately differentiated tumor histological type (p = 0.012) and low expression of H3K4me2 was related to the presence of perineural invasion (p = 0.007). No cellular histone modifications were associated with overall or disease-free survival of patients as a whole. In the subgroup analyses, a low level of H3K4me2 was significantly associated with worse disease free survival in patients that completed adjuvant gemcitabine (p = 0.0239). Univariate and multivariate hazard models also indicated that a low level of H3K4me2 was a significant independent predictor of disease-free survival (p = 0.007). CONCLUSION: H3K4me2 was found to be a predictor of response to adjuvant gemcitabine in Asian patients with pancreatic cancer.
File Format	HTM / HTML
ISSN	07487983
Issue Number	11
Volume Number	38
e-ISSN	15322157
Journal	European Journal of Surgical Oncology (EJSO)
Language	English
Publisher	Elsevier
Publisher Date	2012-11-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline General Surgery Discipline Oncology Antimetabolites, Antineoplastic Therapeutic Use Deoxycytidine Analogs & Derivatives Histones Metabolism Pancreatic Neoplasms Surgery Adult Aged Aged, 80 And Over Chemotherapy, Adjuvant Disease-free Survival Female Humans Immunohistochemistry Lysine Male Methylation Middle Aged Journal Article Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Surgery Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer: A Meta-analysis.

Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms.

Chemotherapy: Gemcitabine remains the standard of care for pancreatic cancer.

A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer.

Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.

Portal vein infusion chemotherapy with gemcitabine after surgery for pancreatic cancer.

Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival.

Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine.

Efficacy of gemcitabine-based chemotherapy in metastatic breast cancer: a meta-analysis of randomized controlled trials.

The cellular level of histone H3 lysine 4 dimethylation correlates with response to adjuvant gemcitabine in Japanese pancreatic cancer patients treated with surgery.

Similar Documents

Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer: A Meta-analysis.

Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms.

Chemotherapy: Gemcitabine remains the standard of care for pancreatic cancer.

A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer.

Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.

Portal vein infusion chemotherapy with gemcitabine after surgery for pancreatic cancer.

Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival.

Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine.

Efficacy of gemcitabine-based chemotherapy in metastatic breast cancer: a meta-analysis of randomized controlled trials.

The cellular level of histone H3 lysine 4 dimethylation correlates with response to adjuvant gemcitabine in Japanese pancreatic cancer patients treated with surgery.